48,460
edits
Difference between revisions of "TRK fusions"
Jump to navigation
Jump to search
→Drugs
(→Drugs) |
|||
| Line 18: | Line 18: | ||
==Drugs== | ==Drugs== | ||
*Merestinib. | *Merestinib. | ||
*Larotrectinib. | *Larotrectinib.<ref name=pmid29466156>{{Cite journal | last1 = Drilon | first1 = A. | last2 = Laetsch | first2 = TW. | last3 = Kummar | first3 = S. | last4 = DuBois | first4 = SG. | last5 = Lassen | first5 = UN. | last6 = Demetri | first6 = GD. | last7 = Nathenson | first7 = M. | last8 = Doebele | first8 = RC. | last9 = Farago | first9 = AF. | title = Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. | journal = N Engl J Med | volume = 378 | issue = 8 | pages = 731-739 | month = 02 | year = 2018 | doi = 10.1056/NEJMoa1714448 | PMID = 29466156 }}</ref> | ||
*Others. | *Others. | ||